Clarify Health, which uses social determinants of health data to inform decision making as part of its healthcare analytics service, raises $115M Series C
Anuja Vaidya / MedCity News :
Context & Ripple Effects
This round lands mid-way through a funding staircase in social-determinants-of-health analytics: Socially Determined's $11.1M Series A in early 2020 seeded the niche, and Aetion's $82M Series B later that year showed generalist healthcare analytics investors would fund it. By the time HealthVerity pulled a $100M Series D for patient-data management in mid-2021, the category had moved from proof-of-concept to scale capital.
Clarify Health's $115M Series C is the largest check yet aimed specifically at SDOH-informed decision making, and the bet paid forward: within roughly a year it raised a $150M Series D at a reported $1.4B valuation, with its dataset covering 300M+ Americans.
First-order effects
- Clarify Health gets the war chest to widen its analytics service and sign larger payer and provider customers while rivals Aetion and Socially Determined are still a funding tier below.
Second-order effects
- Competitors in SDOH and real-world data — Socially Determined, Aetion, HealthVerity — face pressure to raise bigger rounds or merge, since dataset breadth is becoming the product and breadth is expensive.
Third-order effects
- If dataset scale keeps deciding winners, healthcare analytics consolidates around a few large data platforms, and payers begin pricing care and contracts on social determinants as a standard input rather than an experimental one.
The trend: Healthcare analytics is consolidating around scaled real-world and social-determinants datasets, with each successive mega-round raising the capital bar for staying independent.